Effect of thymosin alpha 1 on the antitumor activity of tumor-associated macrophage-derived dendritic cells.
Shrivastava. Pratima P; Singh. Sukh Mahendra SM; Singh. Nisha N
Key Findings
- Thymosin‑alpha‑1 pushes tumor‑associated macrophages to become dendritic cells in mice
- Dendritic cells derived after thymosin‑alpha‑1 treatment produce more IL‑1 and TNF‑alpha
- Adoptive transfer of these cells delays tumor growth and extends survival in tumor‑bearing mice
Practical Outcomes
- The data suggest thymosin‑alpha‑1 can boost certain anti‑tumor immune functions, but the work is limited to mouse models and does not provide dosing or safety info for humans. For biohackers, it’s an interesting hint that the peptide may have immune‑enhancing properties, yet it’s not ready for self‑experimentation or clinical use without further human research.
Summary
In mice with a type of lymphoma, giving the peptide thymosin‑alpha‑1 helped immune cells called tumor‑associated macrophages turn into dendritic cells that were better at fighting the cancer. These new cells released more immune‑signaling molecules and, when transferred to other mice, slowed tumor growth and helped them live longer.
Abstract
We have previously suggested that thymosin alpha(1) (thyalpha1), an immunomodulating thymic hormone, can activate tumor-associated macrophages to a tumoricidal state in a murine model bearing a transplantable T-cell lymphoma of spontaneous origin designated as Dalton's lymphoma (DL). Since tumor-infiltrating dendritic cells (DC) also play an important role in the host's antitumor response and are as such in an immunocompromised state in a tumor-bearing host, in the present investigation we studied if thyalpha1 is able to influence the differentiation of tumor-associated macrophages (TAM) into DC with granulocyte macrophage colony stimulating factor (GM-CSF), interleukin (IL)-4 and tumor necrosis factor (TNF) and whether these TAM-derived DC show enhanced antitumor activity. It was observed that DC generated from thyalpha1-administered tumor-bearing mice showed augmented antitumor activity in vitro. Adoptive immunotherapy using TAM-derived DC showed a significant delay in the tumor growth and a prolongation of the survival time in tumor-bearing mice. DC obtained from TAM of thyalpha1-administered mice also produced an enhanced amount of cytokines like IL-1 and TNF-alpha. This is the first study of its kind regarding the effect of thyalpha1 on the differentiation of DC from TAM and the role of TAM-derived DC in tumor progression.
Study Information
pubmed
2004
10.1007/bf02256128